<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Medical devices</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>FDA, CMS partner to deliver RAPIDly for innovative devices </title>
      <description>
        <![CDATA[The U.S. FDA and CMS are teaming up to give Medicare beneficiaries quicker access to breakthrough medical devices and provide manufacturers with certainty of reimbursement.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730603</guid>
      <pubDate>Thu, 23 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730603-fda-cms-partner-to-deliver-rapidly-for-innovative-devices</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/thumb/CMS-logo-and-website.webp?t=1689968783" type="image/jpeg" medium="image" fileSize="62055">
        <media:title type="plain">CMS logo and website</media:title>
      </media:content>
    </item>
    <item>
      <title>Whoop secures $575M, with Abbott a strategic investor</title>
      <description>
        <![CDATA[Whoop Inc. secured $575 million in a series G funding round at a $10.1 billion valuation to advance its AI-powered wearable platform for personalized and preventive health care. Abbott Laboratories joined the round as a strategic investor, backing the company’s push to expand access to its device amid growing demand.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729965</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729965-whoop-secures-575m-with-abbott-a-strategic-investor</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Whoop-band-3-31.webp?t=1774989701" type="image/jpeg" medium="image" fileSize="320371">
        <media:title type="plain">Whoop health and fitness band</media:title>
        <media:description type="plain">Whoop's wearable health and fitness band provides personalized insights across sleep, recovery, strain, fitness and longevity. Credit: Whoop Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>How to grow a startup in the AI era: MedTech Spotlight Korea 2026 </title>
      <description>
        <![CDATA[AI and advanced biotechnology are reshaping South Korea’s med-tech sector, but great technology alone is not enough to build a successful medical device company, speakers said at MedTech Innovator’s Medtech Spotlight: New Impact Korea 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729896</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729896-how-to-grow-a-startup-in-the-ai-era-medtech-spotlight-korea-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Newco/AI-startup-art-concept.webp?t=1774299523" type="image/jpeg" medium="image" fileSize="387241">
        <media:title type="plain">AI startup art concept</media:title>
      </media:content>
    </item>
    <item>
      <title>How to grow a startup in the AI era: MedTech Spotlight Korea 2026 </title>
      <description>
        <![CDATA[AI and advanced biotechnology are reshaping South Korea’s med-tech sector, but great technology alone is not enough to build a successful medical device company, speakers said at MedTech Innovator’s Medtech Spotlight: New Impact Korea 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729811</guid>
      <pubDate>Mon, 23 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729811-how-to-grow-a-startup-in-the-ai-era-medtech-spotlight-korea-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Newco/AI-startup-art-concept.webp?t=1774299523" type="image/jpeg" medium="image" fileSize="387241">
        <media:title type="plain">AI startup art concept</media:title>
      </media:content>
    </item>
    <item>
      <title>Heart intervention device-maker Insight lands $143M SSE IPO</title>
      <description>
        <![CDATA[Insight Lifetech Co. Ltd. listed on the Shanghai Stock Exchange’s STAR market via an unprofitable biotech track reinstated last year, with the Feb. 5 IPO raising ¥998.64 million (US$143.93 million).]]>
      </description>
      <guid>http://www.bioworld.com/articles/728803</guid>
      <pubDate>Tue, 10 Feb 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728803-heart-intervention-device-maker-insight-lands-143m-sse-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Insight-Lifetech-IPO-ceremony-2-6.webp?t=1770412908" type="image/jpeg" medium="image" fileSize="862498">
        <media:title type="plain">Insight Lifetech IPO ceremony</media:title>
        <media:description type="plain">Insight Lifetech bell-ringing ceremony at the Shanghai Stock Exchange Feb. 5, 2026. Credit: Insight Lifetech Co. Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Heart intervention device-maker Insight lands $143M SSE IPO</title>
      <description>
        <![CDATA[Insight Lifetech Co. Ltd. listed on the Shanghai Stock Exchange’s STAR market via an unprofitable biotech track reinstated last year, with the Feb. 5 IPO raising ¥998.64 million (US$143.93 million).]]>
      </description>
      <guid>http://www.bioworld.com/articles/728662</guid>
      <pubDate>Fri, 06 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728662-heart-intervention-device-maker-insight-lands-143m-sse-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Insight-Lifetech-IPO-ceremony-2-6.webp?t=1770412908" type="image/jpeg" medium="image" fileSize="862498">
        <media:title type="plain">Insight Lifetech IPO ceremony</media:title>
        <media:description type="plain">Insight Lifetech bell-ringing ceremony at the Shanghai Stock Exchange Feb. 5, 2026. Credit: Insight Lifetech Co. Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Medtronic to pay Applied Medical $382M in antitrust ruling</title>
      <description>
        <![CDATA[A jury in a U.S. District Court unanimously found that Medtronic plc violated federal and state antitrust laws relating to its blood sealing surgical devices and must pay $382 million in damages to Applied Medical Resources Corp.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728661</guid>
      <pubDate>Fri, 06 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728661-medtronic-to-pay-applied-medical-382m-in-antitrust-ruling</link>
    </item>
    <item>
      <title>Paragonix’s Kidneyvault extends kidney preservation to 29 hours</title>
      <description>
        <![CDATA[Paragonix Technologies Inc.’s Kidneyvault portable renal perfusion system managed to preserve and enable the reallocation of a donor kidney for more than 29 hours, despite prolonged ischemic time, multiple handoffs and two commercial flights. Throughout the period, the Kidneyvault maintained stable hypothermic preservation, preventing the organ from being discarded and allowing it to be transplanted into a patient.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728660</guid>
      <pubDate>Fri, 06 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728660-paragonixs-kidneyvault-extends-kidney-preservation-to-29-hours</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Paragonix-KidneyVault-2-6.webp?t=1770412909" type="image/jpeg" medium="image" fileSize="218148">
        <media:title type="plain">Paragonix KidneyVault</media:title>
        <media:description type="plain">Paragonix Technologies’ Kidneyvault portable renal perfusion system. Credit: Paragonix Technologies Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA updates cybersecurity guidance for medical devices </title>
      <description>
        <![CDATA[The U.S. FDA released the latest version of its premarket cybersecurity guidance regarding medical devices, replacing the 2025 edition and offering recommendations on implementing measures for preventing digital attacks or authorized access.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728562</guid>
      <pubDate>Wed, 04 Feb 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728562-fda-updates-cybersecurity-guidance-for-medical-devices</link>
    </item>
    <item>
      <title>Zylox-Tonbridge expands to Europe with €18M Optimed buy</title>
      <description>
        <![CDATA[Zylox-Tonbridge Medical Technology Co. Ltd. plans to expand globally with M&As, company chairman and CEO Jonathon Zhong Zhao told BioWorld, starting with a stepwise acquisition of Optimed Holding GmbH and its subsidiaries, including Optimed Medizinische Instrumente GmbH.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728262</guid>
      <pubDate>Wed, 28 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728262-zylox-tonbridge-expands-to-europe-with-18m-optimed-buy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Euro-currency-symbol-white.webp?t=1669153720" type="image/png" medium="image" fileSize="307769">
        <media:title type="plain">White Euro symbol on blue background</media:title>
      </media:content>
    </item>
    <item>
      <title>Rakuten closes $100M series F round, teams with Lotte Biologics</title>
      <description>
        <![CDATA[Rakuten Medical Inc. raised $100 million in a series F round to support late-stage clinical development of ASP-1929, its Alluminox-derived photoimmunotherapy being tested with Keytruda (pembrolizumab) as a first-line treatment for recurrent head and neck cancer. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/728054</guid>
      <pubDate>Tue, 20 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728054-rakuten-closes-100m-series-f-round-teams-with-lotte-biologics</link>
      <media:content url="https://www.bioworld.com/ext/resources/2026/Rakuten-20jan.webp?t=1768944771" type="image/jpeg" medium="image" fileSize="131350">
        <media:title type="plain">Rakuten</media:title>
        <media:description type="plain">(From left) Rakuten Medical COO Abhijit Bhatia, Rakuten Medical President Minami Maeda, Lotte Biologics co-CEOs James Park and Shin Yoo-yeol sign a manufacturing partnership at the J.P. Morgan 2026 Healthcare Conference in San Francsico. Credit: Lotte Biologics</media:description>
      </media:content>
    </item>
    <item>
      <title>China slashes tariffs on some medical devices</title>
      <description>
        <![CDATA[Beginning Jan. 1, 2026, China will apply provisional import tariff rates lower than the most-favored-nation rates on 935 items, the State Council announced. The move aims to boost collaboration between domestic and international sectors, and to leverage resources of both to expand the supply of high-quality goods.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727603</guid>
      <pubDate>Fri, 09 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727603-china-slashes-tariffs-on-some-medical-devices</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/Globe-and-China-flag.webp?t=1766436912" type="image/jpeg" medium="image" fileSize="571448">
        <media:title type="plain">Globe and China flag</media:title>
      </media:content>
    </item>
    <item>
      <title>High pressure areas predicted for 2026 medical device landscape</title>
      <description>
        <![CDATA[It doesn’t take a meteorologist to see the storm clouds of uncertainty that will continue to roll in on health care across the globe this year. While the prospects for the medical device industry may be sunnier than for other aspects of health care, some high pressure areas likely will present challenges.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727593</guid>
      <pubDate>Thu, 08 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727593-high-pressure-areas-predicted-for-2026-medical-device-landscape</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Yellow-umbrella-in-storm.webp?t=1767737642" type="image/jpeg" medium="image" fileSize="639718">
        <media:title type="plain">Yellow umbrella in a storm</media:title>
      </media:content>
    </item>
    <item>
      <title>NMPA aims to tamp down on online sales of med tech</title>
      <description>
        <![CDATA[China’s National Medical Products Administration (NMPA) has issued guidance governing online sales of medical devices with a focus on inspections of the products’ manufacturing facilities. The agency made it clear that the manufacturer will have to deal promptly with any deviations from the regulations or face enforcement action, signaling a new era of tighter scrutiny of online sales of these products.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727572</guid>
      <pubDate>Tue, 06 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727572-nmpa-aims-to-tamp-down-on-online-sales-of-med-tech</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/3D-map-of-China.webp?t=1713912490" type="image/jpeg" medium="image" fileSize="104392">
        <media:title type="plain">3D map of China</media:title>
      </media:content>
    </item>
    <item>
      <title>Advanced Biomed sells Hong Kong subsidiary for $23k </title>
      <description>
        <![CDATA[Advanced Biomed Inc. reported Dec. 30 the sale of its wholly owned Hong Kong subsidiary, Advanced Biomed (HK) Ltd., and related intellectual property to buyer Wei Ha Hui for $23,000.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727303</guid>
      <pubDate>Wed, 31 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727303-advanced-biomed-sells-hong-kong-subsidiary-for-23k</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Advanced-Biomeds-APerfusc-3D-cell-culture-system-(hero)-12-31.webp?t=1767210422" type="image/jpeg" medium="image" fileSize="256616">
        <media:title type="plain">Advanced Biomed’s A+Perfusc 3D cell culture system</media:title>
        <media:description type="plain">Advanced Biomed’s A+Perfusc 3D cell culture system
</media:description>
      </media:content>
    </item>
    <item>
      <title>Bayosthiti AI to build India-specific RNA sequencing ecosystem</title>
      <description>
        <![CDATA[Bayosthiti AI Pvt Ltd. aims to make RNA sequencing and AI-based preventive health care affordable and accessible for the Indian market, leveraging intellectual property from its parent company, Biostate AI Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727660</guid>
      <pubDate>Wed, 31 Dec 2025 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727660-bayosthiti-ai-to-build-india-specific-rna-sequencing-ecosystem</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/thumb/India-digital-map.webp?t=1632951244" type="image/png" medium="image" fileSize="470231">
        <media:title type="plain">India map on technology concept background</media:title>
      </media:content>
    </item>
    <item>
      <title>Intuitive sees continued da Vinci growth amid rising competition</title>
      <description>
        <![CDATA[Intuitive Surgical Inc. strengthened its position as the market leader in robotic-assisted surgery in 2025 on the back of increasing demand for minimally invasive procedures. Intuitive’s da Vinci system is seeing robust growth in procedures and installations, fueling increased revenues.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727297</guid>
      <pubDate>Tue, 30 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727297-intuitive-sees-continued-da-vinci-growth-amid-rising-competition</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/1-24-intuitive-da-vinci-surgeon.webp?t=1602106612" type="image/png" medium="image" fileSize="1745496">
        <media:title type="plain">Surgeon at workstation for surgical robot</media:title>
        <media:description type="plain">Da Vinci surgical system. Credit: Intuitive Surgical Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Laparoscopic instruments maker Livsmed tops 2025 Kosdaq IPOs</title>
      <description>
        <![CDATA[Livsmed Inc. closed the year’s biggest Kosdaq IPO with a ₩135.85 billion (US$94 million) haul Dec. 24. Livsmed specializes in the development of hand-held multi-joint laparoscopic surgical instruments for minimally invasive procedures.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727284</guid>
      <pubDate>Mon, 29 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727284-laparoscopic-instruments-maker-livsmed-tops-2025-kosdaq-ipos</link>
      <media:content url="https://www.bioworld.com/ext/resources/2025/Livsmed-Artisential-29dec25.webp?t=1767041135" type="image/jpeg" medium="image" fileSize="36469">
        <media:title type="plain">Livsmed Artisential</media:title>
        <media:description type="plain">Livsmed Artisential laparoscopic instrument. Credit: Livsmed</media:description>
      </media:content>
    </item>
    <item>
      <title>Crescom wins FDA clearance for bone analysis</title>
      <description>
        <![CDATA[Crescom Co. Ltd., an AI musculoskeletal imaging company, gained U.S. FDA 510(k) clearance Dec. 24 for MediAI-BA, its AI-powered pediatric and adolescent bone age analysis software.
Classified as a class II medical device, MediAI-BA evaluates bone age and suggests predicted adult height based on growth plate status assessed by hand and wrist X-ray imaging. Prior clinical trial results demonstrated MediAI-BA had specialist-level accuracy, recording a mean absolute deviation (MAD) of 0.39 years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727223</guid>
      <pubDate>Wed, 24 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727223-crescom-wins-fda-clearance-for-bone-analysis</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Crescom-MediAI-BA-24dec25.webp?t=1766601685" type="image/jpeg" medium="image" fileSize="71686">
        <media:title type="plain">Crescom MediAI-BA</media:title>
        <media:description type="plain">Crescom MediAI-BA bone age analysis software. Credit: Crescom</media:description>
      </media:content>
    </item>
    <item>
      <title>Bayosthiti AI to build India-specific RNA sequencing ecosystem</title>
      <description>
        <![CDATA[Bayosthiti AI Pvt Ltd. aims to make RNA sequencing and AI-based preventive health care affordable and accessible for the Indian market, leveraging intellectual property from its parent company, Biostate AI Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727213</guid>
      <pubDate>Tue, 23 Dec 2025 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727213-bayosthiti-ai-to-build-india-specific-rna-sequencing-ecosystem</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/thumb/India-digital-map.webp?t=1632951244" type="image/png" medium="image" fileSize="470231">
        <media:title type="plain">India map on technology concept background</media:title>
      </media:content>
    </item>
    <item>
      <title>Nephrodite's Holly renal replacement named breakthrough device</title>
      <description>
        <![CDATA[Nephrodite Inc.'s Holly, an implantable, continuous renal replacement system, received U.S. FDA breakthrough device designation as a novel and potentially life-changing treatment for end-stage kidney disease. The system is designed to enable continuous blood filtration and allow patients freedom to go about their days without frequent, hours-long visits to a dialysis clinic or being hooked up to a filtration system at home.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727065</guid>
      <pubDate>Mon, 15 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727065-nephrodites-holly-renal-replacement-named-breakthrough-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Nephrodite-15dec25.webp?t=1765834885" type="image/jpeg" medium="image" fileSize="172150">
        <media:title type="plain">Nephrodite Holly</media:title>
        <media:description type="plain">Nephrodite Inc.’s Holly renal replacement system Credit: Nephrodite Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>73 Chinese biotech, med-tech companies file for HK IPOs in 2025 </title>
      <description>
        <![CDATA[Seventy-three pharmaceutical, biotechnology and medical device companies from mainland China filed for IPOs in Hong Kong this year, a review by <em>BioWorld&nbsp;</em>found. In the second half of 2025, 43 new securities reports were filed on the Hong Kong Stock Exchange, increasing from the 30 applications in the first half.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726880</guid>
      <pubDate>Tue, 09 Dec 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726880-73-chinese-biotech-med-tech-companies-file-for-hk-ipos-in-2025</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/HKEX-illustration.webp?t=1665175609" type="image/png" medium="image" fileSize="332663">
        <media:title type="plain">HKEX on phone, digital stock chart</media:title>
        <media:description type="plain">Credit: piter2121 - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Epiminder’s AU$125M IPO sets stage for epilepsy breakthrough</title>
      <description>
        <![CDATA[Epiminder Ltd. raised AU$125 million (US$82.99 million) in its initial public offering on the Australian Securities Exchange to commercialize its Minder system, a long-term ambulatory electroencephalography monitoring device for epilepsy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726723</guid>
      <pubDate>Mon, 08 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726723-epiminders-au125m-ipo-sets-stage-for-epilepsy-breakthrough</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/mark-cook-with-minder-implant-24apr25.webp?t=1745526469" type="image/jpeg" medium="image" fileSize="154771">
        <media:title type="plain">Mark Cook with Minder implant</media:title>
        <media:description type="plain">Epiminder Pty Ltd founder and Chief Medical Officer Mark Cook with the Minder implant. Credit: Epiminder</media:description>
      </media:content>
    </item>
    <item>
      <title>Saluda to expand spinal cord stimulation market in AU$231M IPO</title>
      <description>
        <![CDATA[Saluda Medical Pty Ltd. announced a AU$231 million ($152.7 million) initial public offering on the Australian Securities Exchange to scale up its U.S. footprint for its Evoke spinal cord simulation system for chronic pain.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726465</guid>
      <pubDate>Thu, 04 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726465-saluda-to-expand-spinal-cord-stimulation-market-in-au231m-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Evoke-SCS-system-4dec25.webp?t=1764882586" type="image/jpeg" medium="image" fileSize="152734">
        <media:title type="plain">Evoke SCS system</media:title>
        <media:description type="plain">Evoke SCS system. Credit: Saluda Medical Pty Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>China lifts Illumina ban, clears Pacbio’s Sequel II CNDx</title>
      <description>
        <![CDATA[On Nov. 5, the Chinese Ministry of Commerce reported it would lift the export ban on Illumina Inc., which had been in place since March 4. While the ban will be lifted starting Nov. 10, Illumina remains on the unreliable entities list, requiring government approval for instrument purchases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725532</guid>
      <pubDate>Thu, 06 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725532-china-lifts-illumina-ban-clears-pacbios-sequel-ii-cndx</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/pacbio_revio_sequencing_plate-29sept25.webp?t=1759182980" type="image/jpeg" medium="image" fileSize="400158">
        <media:title type="plain">Pacbio Revio sequencing plate</media:title>
        <media:description type="plain">Pacbio’s Revio system can process 100,000 samples per year to identify rare diseases. Credit: Pacific Biosciences of California Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>CG Bio, Nexgel developing long-acting drug delivery system</title>
      <description>
        <![CDATA[Nexgel Biotech Co. Ltd. and CG Bio Co. Ltd. agreed to co-develop a thermosensitive polyphosphazene hydrogel-based long-acting drug delivery platform through a new collaboration agreement signed Oct. 31.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725510</guid>
      <pubDate>Tue, 04 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725510-cg-bio-nexgel-developing-long-acting-drug-delivery-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Collaboration-illustration.webp?t=1600375790" type="image/png" medium="image" fileSize="669559">
        <media:title type="plain">Deal illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Symbyx light therapy shows sustained benefits in Parkinson’s</title>
      <description>
        <![CDATA[The largest study ever conducted on light therapy for Parkinson’s disease has found that long-term use of Symbyx Biome Pty Ltd.’s non-invasive, at-home photobiomodulation (PBM) devices significantly improved mobility, anxiety, and overall symptom severity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725171</guid>
      <pubDate>Fri, 24 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725171-symbyx-light-therapy-shows-sustained-benefits-in-parkinsons</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Symbyx-system-24oct25.webp?t=1761333891" type="image/jpeg" medium="image" fileSize="213101">
        <media:title type="plain">Symbyx system</media:title>
        <media:description type="plain">The PDcare laser is a complementary therapy for reducing Parkinson’s symptoms, with users reporting improvements in motor and non-motor symptoms. Credit: Symbyx</media:description>
      </media:content>
    </item>
    <item>
      <title>US expands tariff investigations into med tech, robotics, diagnostics</title>
      <description>
        <![CDATA[The Trump administration has launched an investigation into the national security effects of imports of medical equipment, devices, consumables and equipment, laying the groundwork for a potential increase in tariffs targeting the industry. A separate investigation into robotics and industrial machinery began the same day. Med-tech stocks dropped significantly in response to the news as investors fear increased tariffs on the sector. In April, the administration initiated a similar review of the pharmaceutical industry and in August threatened 200% tariffs on that sector.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724243</guid>
      <pubDate>Thu, 25 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724243-us-expands-tariff-investigations-into-med-tech-robotics-diagnostics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/Europe-US-Tariffs-Trade-Map.webp?t=1755812059" type="image/jpeg" medium="image" fileSize="893216">
        <media:title type="plain">Wooden blocks spelling TARIFFS with a U.S. flag on top, placed on a map of Europe</media:title>
      </media:content>
    </item>
    <item>
      <title>Korea, Japan ink medical device info sharing pact</title>
      <description>
        <![CDATA[South Korea’s Ministry of Food and Drug Safety signed a confidentiality agreement with Japan’s Ministry of Health, Labour and Welfare and Pharmaceuticals and Medical Devices Agency to boost bilateral regulatory cooperation in the field of medical devices.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722091</guid>
      <pubDate>Wed, 23 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722091-korea-japan-ink-medical-device-info-sharing-pact</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Korea-Japan-23july25.webp?t=1753302955" type="image/jpeg" medium="image" fileSize="348225">
        <media:title type="plain">Korea Japan tech </media:title>
        <media:description type="plain">Left to right: Lee Nam-hee (MFDS), Yumiko Nomura (MHLW) and Kensuke Ishii (PMDA) sign a confidentiality agreement on medical device information sharing, in Tokyo, July 17, 2025.</media:description>
      </media:content>
    </item>
    <item>
      <title>Deepqure expands renal denervation trial to atrial fibrillation</title>
      <description>
        <![CDATA[Deepqure Inc. gained clinical trial clearance from South Korea’s Ministry of Food and Drug Safety to test its Hyperqure renal denervation system for the treatment of atrial fibrillation. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/722081</guid>
      <pubDate>Tue, 22 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722081-deepqure-expands-renal-denervation-trial-to-atrial-fibrillation</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/DeepQure-11june24.webp?t=1718139682" type="image/jpeg" medium="image" fileSize="132378">
        <media:title type="plain">DeepQure</media:title>
        <media:description type="plain">Deepqure. Credit: Deepqure</media:description>
      </media:content>
    </item>
  </channel>
</rss>
